VYGR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
4.0M
+26.8%
3.2M
+22.1%
2.6M
-83.1%
15.3M
+14.7%
13.4M
Cost of Revenue
0
0
0
0
0
Gross Profit
4.0M
+26.8%
3.2M
+22.1%
2.6M
-83.1%
15.3M
+14.7%
13.4M
Operating Expenses
30.4M
+3.0%
29.6M
-10.1%
32.9M
-27.4%
45.3M
+3.0%
44.0M
R&D
24.4M
+10.6%
22.0M
-10.4%
24.6M
-31.6%
36.0M
+0.2%
35.9M
SG&A
6.1M
-19.3%
7.5M
-9.0%
8.3M
-11.3%
9.3M
+15.1%
8.1M
Operating Income
-26422000
-0.1%
-26392000
+12.8%
-30270000
-1.1%
-29932000
+2.2%
-30594000
EBITDA
-25586000
-0.4%
-25484000
+13.1%
-29338000
-1.6%
-28883000
+2.6%
-29662000
Net Income
-24694000
-0.9%
-24473000
+12.4%
-27937000
-1.9%
-27426000
+1.7%
-27892000
EPS (Basic)
$-0.40
+0.0%
$-0.40
+14.9%
$-0.47
+0.0%
$-0.47
+0.0%
$-0.47
EPS (Diluted)
$-0.40
+0.0%
$-0.40
+14.9%
$-0.47
+0.0%
$-0.47
+0.0%
$-0.47
Shares (Diluted)
61.8M
+2.1%
60.5M
+1.8%
59.5M
+0.9%
58.9M
+0.2%
58.8M
Voyager Therapeutics (VYGR) — Financials